Viatris Management

Management criteria checks 1/4

Viatris' CEO is Scott Smith, appointed in Apr 2023, has a tenure of 1.33 years. directly owns 0.007% of the company’s shares, worth MX$16.81M. The average tenure of the management team and the board of directors is 0.7 years and 3.8 years respectively.

Key information

Scott Smith

Chief executive officer

n/a

Total compensation

CEO salary percentage	n/a
CEO tenure	less than a year
CEO ownership	0.007%
Management average tenure	less than a year
Board average tenure	3.8yrs

Recent management updates

Recent updates

CEO

Scott Smith (61 yo)

less than a year

Tenure

Mr. Scott Andrew Smith is Director at Viatris Inc. since December 29, 2022 and serves as its Chief Executive Officer since April 1, 2023. He serves as President of Global Inflammation and Immunology at Cel...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Scott Smith	CEO & Director	less than a year	no data	0.0072% $ 16.8m
Theodora Mistras	Chief Financial Officer	less than a year	no data	no data
Paul Campbell	Chief Accounting Officer	8.9yrs	no data	0.013% $ 30.4m
Ramkumar Rayapureddy	Chief Information Officer	less than a year	no data	no data
Brian Roman	Chief Legal Officer	6.8yrs	no data	0.013% $ 30.9m
Andrew Enrietti	Chief People Officer	3.3yrs	no data	no data
Menassie Taddese	President of Emerging Markets	no data	no data	no data
Derek Glover	Chief Quality Officer	no data	no data	no data
Lara Ramsburg	Chief Corporate Affairs Officer	no data	no data	no data
Jeffrey Nau	President of Viatris Eye Care Division	no data	no data	no data
Philippe Martin	Chief R&D Officer	less than a year	no data	no data
Corinne Le Goff	Chief Commercial Officer	no data	no data	no data

0.7yrs

Average Tenure

52.5yo

Average Age

Experienced Management: VTRS *'s management team is not considered experienced ( 0.7 years average tenure), which suggests a new team.

Board Members

Name	Position	Tenure	Compensation	Ownership
Scott Smith	CEO & Director	1.3yrs	no data	0.0072% $ 16.8m
JoEllen Dillon	Independent Non-Executive Director	10yrs	US$400.00k	0.0050% $ 11.6m
Wyllie Cornwell	Independent Director	3.4yrs	US$370.00k	0.0052% $ 12.1m
Elisha Finney	Independent Director	1.3yrs	no data	0.0016% $ 3.7m
James Kilts	Independent Director	3.4yrs	US$370.00k	0.0099% $ 23.1m
Harry Korman	Independent Non-Executive Director	5.8yrs	US$375.00k	0.0076% $ 17.7m
Melina Higgins	Independent Non-Executive Chairman	11.2yrs	US$445.00k	0.015% $ 34.7m
Robert Coury	Chairman Emeritus & Senior Strategic Advisor	less than a year	US$18.50m	0.053% $ 124.6m
Mark Parrish	Independent Vice Chairman & Lead Independent Director	14.6yrs	US$450.00k	0.010% $ 23.9m
Rajiv Malik	Director	12.3yrs	US$22.55m	0.12% $ 286.7m
Richard Mark	Independent Non-Executive Director	4.3yrs	US$365.00k	0.0061% $ 14.2m
Leo Groothuis	Independent Director	less than a year	no data	0.0019% $ 4.3m

3.8yrs

Average Tenure

62yo

Average Age

Experienced Board: VTRS *'s board of directors are considered experienced (3.8 years average tenure).

Viatris Management

Management criteria checks 1/4

Key information

Recent management updates

President of Developed Markets recently sold Mex$51m worth of stock

Chief Accounting Officer recently sold Mex$4.9m worth of stock

Viatris Announces CFO Changes

Viatris Inc. Appoints Leo Groothuis to Serve on the Compliance and Risk Oversight Committee, Executive Committee and Governance and Sustainability Committee

Viatris Inc., Annual General Meeting, Dec 15, 2023

Viatris Inc. Announces That Its President, Rajiv Malik, Will Be Retiring as an Executive of the Company Effective April 1, 2024

Recent updates

Viatris Inc. to Report Q1, 2024 Results on May 09, 2024

Viatris Inc. Announces Launch of First Bioequivalent Generic Version of Copaxone 20 mg/mL Once-Daily in Canada

Viatris Inc. Announces the Launch of RYZUMVI (Phentolamine Ophthalmic Solution) 0.75% in the United States

President of Developed Markets recently sold Mex$51m worth of stock

Insud Pharma S.L.U. acquired Women Healthcare business of Viatris Inc. (NasdaqGS:VTRS).

Chief Accounting Officer recently sold Mex$4.9m worth of stock

Fourth quarter dividend of US$0.12 announced

Full year 2023 earnings released: EPS: US$0.046 (vs US$1.72 in FY 2022)

Viatris Inc. Declares Quarterly Dividend, Payable on March 18, 2024

Viatris Inc. to Report Fiscal Year 2023 Results on Feb 28, 2024

Viatris Announces CFO Changes

Viatris Inc. Appoints Leo Groothuis to Serve on the Compliance and Risk Oversight Committee, Executive Committee and Governance and Sustainability Committee

Upcoming dividend of US$0.12 per share at 5.2% yield

Third quarter 2023 earnings released: EPS: US$0.28 (vs US$0.29 in 3Q 2022)

Viatris Inc. Declares Quarterly Dividend, Payable on December 15, 2023

Viatris Inc., Annual General Meeting, Dec 15, 2023

Viatris Inc. Announces That Its President, Rajiv Malik, Will Be Retiring as an Executive of the Company Effective April 1, 2024

Viatris Inc. to Report Q3, 2023 Results on Nov 07, 2023

Viatris Inc. and Ocuphire Pharma, Inc. Announce Fda Approval of Ryzumvl™? (Phentolamine Ophthalmic Solution) 0.75% Eye Drops for the Treatment of Pharmacologically-Induced Mydriasis Produced by Adrenergic Agonists (E.G., Tropicamide) Agents

Viatris Reportedly in Talks to Sell European OTC Assets to CVC

Viatris Inc. Announces U.S. FDA Tentative Approval of Paediatric Formulation of Abacavir (ABC)/Dolutegravir (DTG)/Lamivudine (3TC), Once-Daily Treatment for Children Living with HIV

Upcoming dividend of US$0.12 per share at 4.3% yield

Viatris Inc. Declares Quarterly Dividend, Payable on September 15, 2023

Second quarter 2023 earnings released: EPS: US$0.22 (vs US$0.26 in 2Q 2022)

Viatris Inc. and Kindeva Drug Delivery L.P. Announces Launch of Breyna (Budesonide and Formoterol Fumarate Dihydrate) Inhalation Aerosol

Viatris Inc. to Report Q2, 2023 Results on Aug 07, 2023

Holzer & Holzer, LLC Announces A Class Action Lawsuit Has Been Filed Against Viatris Inc

Viatris Inc. Announces Board Changes

Johnson Fistel, LLP Files Class Action Lawsuit Against Viatris Inc

Upcoming dividend of US$0.12 per share at 5.1% yield

First quarter 2023 earnings released: EPS: US$0.19 (vs US$0.33 in 1Q 2022)

Viatris Inc. Reaffirms Revenue Guidance for the Full-Year 2023

Full year 2022 earnings released: EPS: US$1.72 (vs US$1.05 loss in FY 2021)

Biocon Plans to Sell Stake in Biologics Arm to Pare Debt

Viatris Inc. to Report Q4, 2022 Results on Feb 27, 2023

Viatris Inc. (NasdaqGS:VTRS) completed the acquisition of Oyster Point Pharma, Inc. (NasdaqGS:OYST) from a group of shareholders.

Viatris Inc. Announces Changes to its Board

Investor sentiment improved over the past week

Viatris Inc. Announces Approval of Emissions Reduction Targets by the Science Based Target Initiative

Biocon Biologics Limited completed the acquisition of biosimilars portfolio and related commercial and operational capabilities from Viatris Inc. (NasdaqGS:VTRS).

Viatris Inc. (NasdaqGS:VTRS) entered into a definitive agreement to acquire Oyster Point Pharma, Inc. (NasdaqGS:OYST) for approximately $300 million.

Viatris Inc. Reaffirms Revenue Guidance for the Full Year 2022

Viatris Inc., Annual General Meeting, Dec 09, 2022

Viatris Inc., Annual General Meeting, Dec 09, 2022

Viatris Inc. to Report Q3, 2022 Results on Nov 07, 2022

Viatris Reportedly Considers Sale of $3 Billion European OTC Assets

Independent Non-Executive Director recently sold Mex$2.0m worth of stock

Upcoming dividend of US$0.12 per share

Viatris Inc. Declares Quarterly Dividend, Payable on September 16, 2022

Second quarter 2022 earnings released: EPS: US$0.26 (vs US$0.23 loss in 2Q 2021)

Viatris Inc. to Report Q2, 2022 Results on Aug 08, 2022

Insider recently sold Mex$2.1m worth of stock

First quarter 2022 earnings released: EPS: US$0.33 (vs US$0.86 loss in 1Q 2021)

Viatris Declares Quarterly Dividend, Payable on June 16, 2022

Viatris Inc. to Report Q1, 2022 Results on May 09, 2022

Executive Chairman of the Board recently sold Mex$107m worth of stock

Executive Chairman of the Board recently sold Mex$107m worth of stock

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Viatris Inc. (NasdaqGS:VTRS) announces an Equity Buyback for $1,000 million worth of its shares.

Upcoming dividend of US$0.12 per share

Viatris Inc. to Report Q4, 2021 Results on Feb 28, 2022

Viatris Wins Court Decisions on Sanofi Appeals of Lantus Patent Invalidations

Viatris Wins Federal Circuit Court Appeal Upholding District Court Decision Invalidating Biogen's Tecfidera Patent

Third quarter 2021 earnings released: EPS US$0.26 (vs US$0.36 in 3Q 2020)

Second quarter 2021 earnings released: US$0.23 loss per share (vs US$0.076 profit in 2Q 2020)

Viatris Inc.(NasdaqGS:VTRS) dropped from Russell 1000 Value-Defensive Index

Mylan Wins Significant Summary Judgment Rulings in Kansas Epipen® Class Action

Aurobindo Pharma Limited (NSEI:AUROPHARMA) agreed to acquire Cold-EEZE Business of Viatris Inc. from Viatris Inc. (NasdaqGS:VTRS).

Independent Director recently bought Mex$627k worth of stock